Acadia Pharmaceuticals (ACAD) Profit After Tax (2010 - 2026)

Acadia Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 80.84% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $375.6 million (up 64.12% YoY), while the FY2025 annual figure was $391.0 million, up 72.66% from the prior year.
• Profit After Tax was $3.6 million for Q1 2026 at Acadia Pharmaceuticals, down from $273.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $273.6 million in Q4 2025 to a low of -$113.1 million in Q1 2022.
• Historically, Profit After Tax has averaged $20.2 million across 5 years, with a median of $16.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax tumbled 139.77% in 2023, then jumped 2897.22% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$41.7 million in 2022, then surged by 209.76% to $45.8 million in 2023, then jumped by 213.87% to $143.7 million in 2024, then surged by 90.32% to $273.6 million in 2025, then slumped by 98.67% to $3.6 million in 2026.
• The last three Profit After Tax figures came in at $3.6 million (Q1 2026), $273.6 million (Q4 2025), and $71.8 million (Q3 2025), per Business Quant data.